In the last trading session, 77823.0 shares of the SAB Biotherapeutics Inc (NASDAQ:SABS) were traded, and its beta was 0.47. Most recently the company’s share price was $3.53, and it changed around -$0.03 or -0.84% from the last close, which brings the market valuation of the company to $32.58M. SABS currently trades at a discount to its 52-week high of $6.30, offering almost -78.47% off that amount. The share price’s 52-week low was $2.16, which indicates that the current value has risen by an impressive 38.81% since then. We note from SAB Biotherapeutics Inc’s average daily trading volume that its 10-day average is 57460.0 shares, with the 3-month average coming to 79.71K.
SAB Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended SABS as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. SAB Biotherapeutics Inc is expected to report earnings per share of -1.21 for the current quarter.
SAB Biotherapeutics Inc (NASDAQ:SABS) trade information
Instantly SABS has showed a red trend with a performance of -0.84% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.84 on recent trading dayincreased the stock’s daily price by 8.07%. The company’s shares are currently down -6.96% year-to-date, but still down -8.07% over the last five days. On the other hand, SAB Biotherapeutics Inc (NASDAQ:SABS) is -10.86% down in the 30-day period. We can see from the shorts that 36467.0 shares have been sold at a short interest cover period of 0.4 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 41.17% from its current value. Analyst projections state that SABS is forecast to be at a low of $3 and a high of $8.
SAB Biotherapeutics Inc (SABS) estimates and forecasts
SAB Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 23.86 percent over the past six months and at a 51.70% annual growth rate that is well above the industry average of 16.50%. The year-over-year growth rate is expected to be -39.94%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 120k in revenue for the current quarter. 3 analysts expect SAB Biotherapeutics Inc to make 333.33k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 305.01k and 944.58k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -60.66%. Forecasts for the next quarter put sales growth at -64.71%.
SABS Dividends
SAB Biotherapeutics Inc’s next quarterly earnings report is expected to be released in February.
SAB Biotherapeutics Inc (NASDAQ:SABS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 19.15% of SAB Biotherapeutics Inc shares, and 35.64% of them are in the hands of institutional investors. The stock currently has a share float of 44.08%.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 232.57 shares worth $0.82 million, making up 2.52% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 42.64 shares worth around $0.15 million, which represents about 0.46% of the total shares outstanding.
